RO.CH

331

+1.97%↑

NOVN.CH

118.34

+0.8%↑

LONN.CH

542

+1.84%↑

SDZ.CH

66.38

+1.22%↑

STMN.CH

92.32

+4.43%↑

RO.CH

331

+1.97%↑

NOVN.CH

118.34

+0.8%↑

LONN.CH

542

+1.84%↑

SDZ.CH

66.38

+1.22%↑

STMN.CH

92.32

+4.43%↑

RO.CH

331

+1.97%↑

NOVN.CH

118.34

+0.8%↑

LONN.CH

542

+1.84%↑

SDZ.CH

66.38

+1.22%↑

STMN.CH

92.32

+4.43%↑

RO.CH

331

+1.97%↑

NOVN.CH

118.34

+0.8%↑

LONN.CH

542

+1.84%↑

SDZ.CH

66.38

+1.22%↑

STMN.CH

92.32

+4.43%↑

RO.CH

331

+1.97%↑

NOVN.CH

118.34

+0.8%↑

LONN.CH

542

+1.84%↑

SDZ.CH

66.38

+1.22%↑

STMN.CH

92.32

+4.43%↑

Home・Aandelen Lijst・Bachem Holding AG

Bachem Holding AG

Gesloten

SectorGezondheidszorg

69.7 -1.13

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

69.6

Max

70.85

Belangrijke statistieken
By Trading Economics
Inkomsten	49M 99M
Verkoop	69M 382M
K/W Sectorgemiddelde	36.692 63.808
EPS	1.317
Dividendrendement	1.29
Winstmarge	25.83
Werknemers	2,130
EBITDA	35M 107M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+19.94% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	1.29% 2.38%

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.4B 5.4B
Vorige openingsprijs	70.83
Vorige sluitingsprijs	69.7

Bachem Holding AG Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 apr 2026, 20:26 UTC

Acquisities, Fusies, Overnames

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17 apr 2026, 18:15 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17 apr 2026, 16:49 UTC

Belangrijke Nieuwsgebeurtenissen

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17 apr 2026, 16:49 UTC

Belangrijke Nieuwsgebeurtenissen

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17 apr 2026, 22:58 UTC

Winsten

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 apr 2026, 21:32 UTC

Marktinformatie

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 apr 2026, 21:22 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 apr 2026, 21:22 UTC

Marktinformatie

Moody's Downgrades Belgium to A1 -- Market Talk

17 apr 2026, 20:52 UTC

Winsten

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 apr 2026, 20:50 UTC

Marktinformatie

Winsten

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

17 apr 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

17 apr 2026, 20:29 UTC

Winsten

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17 apr 2026, 20:11 UTC

Acquisities, Fusies, Overnames

UCB to Buy Neurona Therapeutics for Up to $1.15B

17 apr 2026, 19:34 UTC

Marktinformatie

Winsten

Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

17 apr 2026, 19:34 UTC

Marktinformatie

Winsten

Acquisities, Fusies, Overnames

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17 apr 2026, 19:31 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17 apr 2026, 19:26 UTC

Marktinformatie

U.S. Natural Gas Futures Edge Up -- Market Talk

17 apr 2026, 19:21 UTC

Marktinformatie

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17 apr 2026, 19:15 UTC

Marktinformatie

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 apr 2026, 19:07 UTC

Marktinformatie

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 apr 2026, 18:57 UTC

Belangrijke Nieuwsgebeurtenissen

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17 apr 2026, 18:53 UTC

Acquisities, Fusies, Overnames

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17 apr 2026, 18:53 UTC

Acquisities, Fusies, Overnames

UCB 2026 Rev Guidance Unchanged

17 apr 2026, 18:52 UTC

Acquisities, Fusies, Overnames

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17 apr 2026, 18:52 UTC

Acquisities, Fusies, Overnames

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17 apr 2026, 18:14 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17 apr 2026, 18:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17 apr 2026, 18:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17 apr 2026, 17:31 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17 apr 2026, 17:26 UTC

Marktinformatie

Winsten

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Peer Vergelijking

Prijswijziging

Bachem Holding AG Prognose

Koersdoel

By TipRanks

19.94% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 84.2 CHF 19.94%

Hoogste 110 CHF

Laagste 65 CHF

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bachem Holding AG - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Bachem Holding AG - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Bachem Holding AG

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was founded in 1971 and is headquartered in Bubendorf, Switzerland.